CY1109151T1 - Αντισωματα dr4 και χρησεις αυτων - Google Patents

Αντισωματα dr4 και χρησεις αυτων

Info

Publication number
CY1109151T1
CY1109151T1 CY20091100634T CY091100634T CY1109151T1 CY 1109151 T1 CY1109151 T1 CY 1109151T1 CY 20091100634 T CY20091100634 T CY 20091100634T CY 091100634 T CY091100634 T CY 091100634T CY 1109151 T1 CY1109151 T1 CY 1109151T1
Authority
CY
Cyprus
Prior art keywords
antibodies
accessories
kits
diagnosis
articles
Prior art date
Application number
CY20091100634T
Other languages
Greek (el)
English (en)
Inventor
Avi J Ashkenazi
Anan Chuntharapai
Kelly H Dodge
Kyung Jin Kim
Original Assignee
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech, Inc. filed Critical Genentech, Inc.
Publication of CY1109151T1 publication Critical patent/CY1109151T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
CY20091100634T 1999-05-28 2009-06-16 Αντισωματα dr4 και χρησεις αυτων CY1109151T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32287599A 1999-05-28 1999-05-28
EP00937844A EP1181319B1 (en) 1999-05-28 2000-05-25 Chimeric dr4 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
CY1109151T1 true CY1109151T1 (el) 2014-07-02

Family

ID=23256824

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100634T CY1109151T1 (el) 1999-05-28 2009-06-16 Αντισωματα dr4 και χρησεις αυτων

Country Status (12)

Country Link
EP (2) EP2213302A3 (enExample)
JP (1) JP4589586B2 (enExample)
AT (1) ATE429450T1 (enExample)
AU (3) AU781952B2 (enExample)
CA (1) CA2374599A1 (enExample)
CY (1) CY1109151T1 (enExample)
DE (1) DE60042066D1 (enExample)
DK (1) DK1181319T3 (enExample)
ES (1) ES2325305T3 (enExample)
IL (1) IL146448A0 (enExample)
PT (1) PT1181319E (enExample)
WO (1) WO2000073349A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE352618T1 (de) 1997-03-17 2007-02-15 Human Genome Sciences Inc Rezeptor 5, der eine für den zelltod verantwortliche domäne enthält
US6872568B1 (en) 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
CA2369371A1 (en) * 1999-05-04 2000-11-09 Human Genome Sciences, Inc. Death domain containing receptor 5
PT1181319E (pt) * 1999-05-28 2009-07-14 Genentech Inc Anticorpos quiméricos contra dr4 e suas utilizações
US7476383B2 (en) 2000-05-02 2009-01-13 The Uab Research Foundation Antibody selective for DR4 and uses thereof
US7279160B2 (en) 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
WO2002094880A1 (fr) * 2001-05-18 2002-11-28 Kirin Beer Kabushiki Kaisha Anticorps anti-trail-r
CA2446723C (en) * 2001-05-25 2014-01-21 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
US7361341B2 (en) 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
WO2003066661A2 (en) * 2001-07-03 2003-08-14 Genentech, Inc. Human dr4 antibodies and uses thereof
WO2003013584A1 (en) * 2001-08-09 2003-02-20 Genset S.A. Xafinix agonists and antagonists for use in the treatment of metabolic disorders
ES2357225T3 (es) * 2001-11-01 2011-04-20 Uab Research Foundation Combinaciones de anticuerpos anti-dr5 y anticuerpos anti-dr4 y otros agentes terapéuticos.
RU2395294C2 (ru) * 2004-06-18 2010-07-27 Дженентек, Инк. Способы применения агонистов аро-2l-рецепторов и активаторов nk-клеток
MX2007001469A (es) 2004-08-06 2007-03-26 Genentech Inc Ensayos y metodos que utilizan biomarcadores.
WO2006017859A2 (en) 2004-08-06 2006-02-16 Genentech, Inc. Assays and methods using biomarkers
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US8029783B2 (en) * 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
CN101495646A (zh) 2005-02-02 2009-07-29 Uab研究基金会 与降低对细胞凋亡诱导性死亡受体激动剂的抗性有关的试剂和方法
AU2006279618A1 (en) 2005-08-16 2007-02-22 Genentech, Inc. Apoptosis sensitivity to Apo2L/TRAIL by testing for 'GalNac-T14 expression in cells/tissues
WO2008066854A2 (en) * 2006-11-28 2008-06-05 Novartis Ag Methods and compositions for inducing apoptosis in cancer cells
CA2680237C (en) 2007-03-27 2018-11-06 Sea Lane Biotechnologies, Llc Constructs and libraries comprising antibody surrogate light chain sequences
WO2010132604A2 (en) 2009-05-13 2010-11-18 Sea Lane Biotechnologies, Llc Neutralizing molecules to influenza viruses
EP2704735A1 (en) 2011-05-03 2014-03-12 Genentech, Inc. Vascular disruption agents and uses thereof
US10300140B2 (en) 2011-07-28 2019-05-28 I2 Pharmaceuticals, Inc. Sur-binding proteins against ERBB3
CA2859744A1 (en) * 2011-12-22 2013-06-27 Sea Lane Biotechnologies, Llc Surrogate binding proteins
CN110305874A (zh) * 2019-06-19 2019-10-08 浙江省肿瘤医院 长爪沙鼠免疫球蛋白IgG1、IgG2重组蛋白、基因及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP0626012B1 (en) 1992-02-11 2003-07-09 Cell Genesys, Inc. Homogenotization of gene-targeting events
EP1012274B2 (en) * 1997-01-28 2011-06-15 Human Genome Sciences, Inc. Death domain containing receptor 4 (dr4: death receptor 4), member of the tnf-receptor superfamily and binding to trail (ap0-2l)
ES2293682T5 (es) * 1997-05-15 2011-11-17 Genentech, Inc. Anticuerpo anti-apo2.
JP2002500877A (ja) * 1998-01-26 2002-01-15 ジェネンテク・インコーポレイテッド 細胞死レセプター４（ｄｒ４）に対する抗体及びその使用
ES2395693T3 (es) * 1998-06-12 2013-02-14 Genentech, Inc. Anticuerpos monoclonales, anticuerpos que reaccionan de forma cruzada y procedimiento para la fabricación de los mismos
PT1181319E (pt) * 1999-05-28 2009-07-14 Genentech Inc Anticorpos quiméricos contra dr4 e suas utilizações

Also Published As

Publication number Publication date
AU781952B2 (en) 2005-06-23
DK1181319T3 (da) 2009-08-17
EP1181319A1 (en) 2002-02-27
AU2005201915B2 (en) 2009-01-22
JP4589586B2 (ja) 2010-12-01
ES2325305T3 (es) 2009-09-01
EP2213302A3 (en) 2010-11-03
IL146448A0 (en) 2002-07-25
JP2003503017A (ja) 2003-01-28
DE60042066D1 (de) 2009-06-04
ATE429450T1 (de) 2009-05-15
CA2374599A1 (en) 2000-12-07
WO2000073349A9 (en) 2002-05-10
EP2213302A2 (en) 2010-08-04
AU2005201915A1 (en) 2005-06-02
AU2009201670A1 (en) 2009-05-21
WO2000073349A1 (en) 2000-12-07
AU5296700A (en) 2000-12-18
PT1181319E (pt) 2009-07-14
EP1181319B1 (en) 2009-04-22

Similar Documents

Publication Publication Date Title
CY1109151T1 (el) Αντισωματα dr4 και χρησεις αυτων
CY1110505T1 (el) Ανθρωπινα αντισωματα dr4 και χρησεις αυτων
CY1111863T1 (el) Αντισωματα εναντιον υποδοχεα θανατου 4 (dr4) και χρησεις αυτων
CY2020003I2 (el) Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις για την θεραπευτικη αγωγη της παθολογιας του crohn
CA2258153A1 (en) Hepatocyte growth factor receptor agonists and uses thereof
CY1119742T1 (el) Βιολογικα συστηματα μεταφορας πολλαπλου-συστατικου
TR200002773T2 (tr) Alzheimer tedavisi için smilagenin ve anzurogenin-D ve bunların kullanımı.
DE69913884D1 (de) Photohärtbare Zusammensetzung und lichtgehärtete geformte Gegenstände
TR199903331T2 (xx) Farnesil protein transferas engelleyicileri.
ATE225341T1 (de) In 6-position durch thio substituierte paclitaxele
TR199902803T2 (xx) VCAM-1' in te�hisinin daralt�lmas� i�in bile�ikler ve metodlar.
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
PT1560812E (pt) Compostos de aminociclohexil eter e suas utilizacoes
ES2157886T3 (es) Composiciones tensioactivas y procedimientos.
TR200001102T2 (tr) İkameli tetrahidropirimidinen türevleri, üretimleri ve kullanımları.
TR200000291T2 (tr) Taşikinin reseptör antagonistleri olarak 2-asilaminopropanaminler.
DE60043616D1 (de) Herstellung von verbindungen zur bestimmung der hypoxie
ID25478A (id) Agonis 5-ht1f
DE69612056D1 (de) Terpenderivate (sarcodictyine) als antikrebsmittel
DK0647654T3 (da) Anomere fluor-ribosylaminer
SE8802323D0 (sv) 8alfa-acylaminoergoline, its preparation and pharmaceutical compositions containing it
DE59706692D1 (de) Konjugat, geeignet zur bindung von substanzen